Srpski | Русский | Deutsch | Nederlands
The lines between the brows are often the first to signal tension and fatigue, even when we feel rested. Letybo is one of the newest botulinum toxins on the global market, backed by three large phase 3 clinical trials.
What is Letybo?
Letybo (letibotulinumtoxinA-wlbg) is a botulinum toxin type A from the South Korean company Hugel, produced from Clostridium botulinum strain CBFC26. It was approved in the United States in 2024 for the temporary improvement of moderate to severe frown lines between the brows in adults.
How does it work?
Like every botulinum toxin type A, Letybo temporarily blocks the release of acetylcholine at the nerve-muscle junction, so the treated muscle creases the skin less. This softens dynamic wrinkles – the lines created by repeated facial movement – while the rest of the face keeps its natural expression. The effect is temporary and limited to the treated area.
What did the clinical trials show?
Three large phase 3 trials (BLESS I, II and III), with more than 1,200 participants in the United States and the European Union, measured the improvement of frown lines. After four weeks, 47-65% of people treated with Letybo showed meaningful improvement, compared with 0-2% on placebo. The effect typically appeared within three days, and the average time to retreatment was about four months. The most common side effects were headache and temporary reactions at the injection site.
Letybo, Botox or Xeomin?
All three products contain botulinum toxin type A and work the same way: they calm the muscle that creates the line. Botox has been in aesthetic use in the United States since 2002 and is approved there for forehead lines and crow’s feet as well, while Letybo’s US approval covers frown lines only. Xeomin is a purified toxin without complexing proteins, while Letybo and Botox are toxin complexes with accompanying proteins. For all three, the effect develops gradually over several days and is temporary, so treatments are repeated after a few months. The trials behind Letybo’s approval compared it with placebo, not with other toxins, so its speed and duration cannot be compared directly with Botox or Xeomin. Unit doses are not interchangeable between products. The choice depends on anatomy, muscle strength, previous experience and the clinician’s assessment.
Before treatment
Botulinum toxin treatment is not suitable with an infection at the injection site or a known hypersensitivity to any component. Tell your clinician if you are pregnant, breastfeeding or planning a pregnancy, if you have a neuromuscular condition, and about all medicines you take – especially those affecting muscles or blood clotting – as well as any previous botulinum toxin treatments. Treatments are not repeated more often than every three months.
Risks to understand
The most common side effects are headache and temporary redness, tenderness or swelling at the injection site. A drooping eyelid or brow can occur rarely. Like all botulinum toxins, Letybo carries a warning about possible spread of the toxin’s effect beyond the injection area; if you notice difficulty swallowing, speaking or breathing, seek medical help immediately.
Discuss your goal
If you are considering treatment for frown lines, an ESTERA consultation assesses your facial movement, muscle strength and expectations, so the product and plan are chosen for your face. The choice of toxin comes after the assessment, not before it.
Frequently asked questions
Is Letybo the same as Botox?
No. Both are botulinum toxins type A, but they are made by different companies and differ in formulation. Unit doses are not interchangeable between products.
When will I see the first result?
In studies, the effect typically appeared within three days, and in some participants earlier. The full effect is assessed after about two to four weeks.
How long does the effect last?
In trials, the effect lasted up to about 16 weeks, with retreatment on average planned after four months. Duration depends on the person, the dose and the treated area.
Can I switch from another toxin to Letybo?
Switching is possible with a clinician’s assessment and proper intervals between treatments. Doses are not transferred automatically, because units are not interchangeable.
Sources
- FDA Prescribing Information: LETYBO (letibotulinumtoxinA-wlbg), 2024
- FDA Drug Trials Snapshot: LETYBO
- Mueller DS et al., Aesthetic Surgery Journal 2022;42(6):677-688, doi:10.1093/asj/sjac019
- Croma-Pharma press releases on European approvals and the Letybo launch, 2022-2023
- Letybo USA, official product site (letybousa.com)
